UniProt Q6IQ55 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic domain (aa1-331)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Capivasertib | 30.0% | 70.0% | 96.48 | 0.644 |
| 2 | Vemurafenib | 24.9% | 75.1% | 96.49 | 0.598 |
| 3 | Baricitinib | 20.8% | 79.2% | 97.99 | 0.616 |
| 4 | Regorafenib | 20.4% | 79.6% | 95.99 | 0.719 |
| 5 | Trametinib | 20.1% | 79.9% | 99.50 | 0.718 |
| 6 | Binimetinib | 20.0% | 80.0% | 100.00 | 0.689 |
| 7 | Lapatinib | 19.9% | 80.1% | 99.25 | 0.616 |
| 8 | Bosutinib | 19.6% | 80.4% | 87.22 | 0.555 |
| 9 | Sirolimus | 16.0% | 84.0% | 100.00 | 0.708 |
| 10 | Nilotinib | 15.9% | 84.1% | 96.49 | 0.765 |
| 11 | Everolimus | 15.6% | 84.4% | 100.00 | 0.706 |
| 12 | Ruxolitinib | 15.1% | 84.9% | 98.25 | 0.592 |
| 13 | Dasatinib | 14.2% | 85.8% | 87.97 | 0.699 |
| 14 | Afatinib | 14.1% | 85.9% | 98.50 | 0.709 |
| 15 | Temsirolimus | 13.6% | 86.4% | 100.00 | 0.740 |
| 16 | Gefitinib | 13.1% | 86.9% | 99.25 | 0.650 |
| 17 | Acalabrutinib | 12.9% | 87.1% | 99.50 | 0.670 |
| 18 | Cabozantinib | 12.8% | 87.2% | 92.73 | 0.751 |
| 19 | Nintedanib | 10.8% | 89.2% | 90.23 | 0.608 |
| 20 | Crizotinib | 10.7% | 89.3% | 91.39 | 0.581 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.23
- Epithelial log2(TPM+1): 1.75
- Fold change: 0.48
- Status: No significant change
Selectivity landscape vs inhibition on TTBK2
Each point is one of the 92 approved drugs; color = inhibition % on TTBK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…